GRFS vs. CNTX, LVTX, MYNZ, NLSP, PHVS, TLSA, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Context Therapeutics (CNTX), LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Grifols (NASDAQ:GRFS) and Context Therapeutics (NASDAQ:CNTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
Grifols received 338 more outperform votes than Context Therapeutics when rated by MarketBeat users. However, 58.82% of users gave Context Therapeutics an outperform vote while only 55.95% of users gave Grifols an outperform vote.
14.0% of Context Therapeutics shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 6.7% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Grifols and Grifols both had 2 articles in the media. Grifols' average media sentiment score of -0.09 beat Context Therapeutics' score of -0.50 indicating that Grifols is being referred to more favorably in the media.
Grifols currently has a consensus price target of $10.50, indicating a potential upside of 64.58%. Context Therapeutics has a consensus price target of $4.00, indicating a potential upside of 183.67%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Grifols.
Grifols has higher revenue and earnings than Context Therapeutics.
Grifols has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.
Grifols has a net margin of 1.84% compared to Context Therapeutics' net margin of 0.00%. Grifols' return on equity of 1.73% beat Context Therapeutics' return on equity.
Summary
Grifols and Context Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Grifols News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
